Default company panoramic image
Logo

Pulmotect, Inc.

Pulmotect is developing immunomodulation technologies to provide broad protection by boosting the innate immune system of the lungs.

  • Stage Concept Only
  • Industry Biotechnology
  • Location Baytown, TX, USA
  • Currency USD
  • Employees 1
  • Website pulmotect.com

Company Summary

PUL-042, our lead product, stimulates the lung’s natural defenses to provide immediate, safe, and broad-spectrum protection against bacterial pneumonia (including MRSA), viral infections (influenza), fungal pneumonia, and Class A bioterror agents (including anthrax, tularemia, and plague). With core funding available through Phase II trials, the Company is well positioned to explore additional indications and market opportunities.

Team

  • Default avatar
    Brenton Scott
    President

    A co-founder of Pulmotect, Dr. Scott’s graduate and postgraduate experience focused on vesicular traffic, airway inflammation and infection. He serves as the PI on multiple grant awards, including the CPRIT award from the State of Texas. He received his PhD in Biochemistry and Cell Biology from Rice University and his MBA from University of Houston.

  • Default avatar
    Diane Markesich
    Director of Operations

Advisors

  • Default avatar
    Eddy Rogers, Andrews and Kurth
    Lawyer
    Unconfirmed